Curriculum Vitae: June 20, 2016 Ramesh Rengan, MD, Ph.D. 1959 NE Pacific St Department of Radiation Oncology Box 356034 Seattle, WA 6/20/16 98195 Phone: 206-598-4100 Fax: 206-598-7496 Email: rengan@uw.edu

1. Personal Data a. Place of birth: Ypsilanti, MI USA b. Citizenship: US c. Date of birth: 12/31/71

2. Education

a. 1992 B.Sc. University of Michigan College of Literature, Science and the Arts (Chemistry)

b. 1995 M.S. University of Michigan Medical School and Rackham School of Graduate Studies (Biological Chemistry)

c. 2001 M.D. University of Michigan Medical School and Rackham School of Graduate Studies (Biological Chemistry)

d. 2001 Ph.D. University of Michigan Medical School and Rackham School of Graduate Studies (Biological Chemistry)

3. Postgraduate Training and Fellowship Appointments:

a. 1990 Fellow, Summer School in Nuclear Chemistry, Brookhaven National Laboratory

b. 1992-2001 Fellow, Medical Scientist Training Program, University of Michigan School of Medicine

c. 1994-1995 Fellow, Pharmacological Sciences Training Program, University of Michigan Medical School

d. 2002-2006 Resident in Radiation Oncology, Memorial Sloan-Kettering Cancer Center, NY

4. Faculty Positions Held:

a. 2013 Associate Professor of Radiation Oncology at the University of Washington School of Medicine

b. 2006-2013 Assistant Professor of Radiation Oncology at the Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

5. Hospital Positions Held:

a. 2014-Current Medical Director, SCCA Proton Center, Department of Radiation Oncology, University of Washington School of Medicine

b. 2013 Associate Medical Director, SCCA Proton Center, Department of Radiation Oncology, University of Washington School of Medicine

c. 2010-2013 Chief, Thoracic Service, Clinical Division, Department of Radiation Oncology

d. 2012-2013 Assistant Director of Clinical Operations, Department of

Radiation Oncology, University of Pennsylvania

6. Awards, Honors and Membership in Honorary Societies: a. 1989 Finalist, National Merit Scholarship Program b. 1990 Fellowship, Nuclear Chemistry, Brookhaven National Laboratories

(summer session) c. 1992-2001 Fellowship, Medical Scientist Training Program, University of

Michigan Medical School d. 1994-1995 Fellowship, Pharmacological Sciences Training Program, University of

Michigan Medical School e. 1998 Travel Fellowship Society of Leukocyte Biology f. 2002 Preliminary Intern of the Year, St. Mary's Medical Center, San Francisco g. 2004 Young Oncologist Essay Award, American Radium Society h. 2004 Best of ASCO Travel Fellowship, American Society of Clinical

Oncology i. 2005 Educational Travel Grant, 6th Annual Perspectives in Colorectal Cancer,

Chicago j. 2005 Roentgen Resident/Fellow Research Award k. 2007-2009 Junior Faculty Career Research Training Award, American

Society for Therapeutic Radiation and Oncology l. 2007-2008 Junior Investigator Pilot Training Grant, Awarded by Clinical and

Translational Research Center, University of Pennsylvania m. 2008-2009 RSNA Fellowship for Advanced Grant Writing n. 2008-2009 Thomas B. and Jeannette E. Laws McCabe Fund Pilot Award o. 2009 Fellowship, Clinical Trials Methodology, Radiological Society of North

America p. 2012-2014 Pilot Award; Melanoma Research Alliance q. 2013-2014 Faculty Teaching Award, Department of Radiation Oncology,

University of Washington Medical Center r. 2015 Pilot Award; Bezos Family Immunotherapy, Fred Hutchinson Cancer

Research Center

7. Board Certification: a. 2002-Current Diplomat of the National Board of Medical Examiners b. 2007 American Board of Radiology: Board Certification in Radiation

Oncology

8. Licensure: a. 2013-Current Washington State Medical License b. 2002-Current New York State License to Practice Medicine and Surgery c. 2006-Current Commonwealth of Pennsylvania Department of State Bureau of

Professional and Occupational Affairs d. 2006-Current New Jersey State Board of Medical Examiners e. 2006-Current Medical Board of California

9. Memberships in Professional and Scientific Societies and Other Professional Activities:

a. International: i. 2002-Current American Society for Therapeutic Radiology and Oncology

(ASTRO) (Co-Chair IHE-RO Planning Committee, October 2010 to current; Vice Chair, Publications Committee, October 2010 to current)

ii. 2002-Current Radiological Society of North America (RSNA) (Member, RSNA Oncologic Imaging Task Force for the Bolstering Oncoradiologic and Oncoradiotherapeutic Skills for Tomorrow (BOOST) program, July 2008 to current; Member, Radiation Oncology and Radiobiology Subcommittee, October 2009 to current; Member, Scientific Program Committee, July 2010 to current; Content advisory panel)

iii. 2006-Current Member, International Association for the Study of Lung Cancer

iv. 2008-Current Integrating the Healthcare Enterprise (IHE) (Co-Chair, IHE Radiation Oncology Planning Committee)

v. 2008-Current Radiation Therapy Oncology Group (RTOG) (Principal Investigator for University of Pennsylvania RTOG Studies)

vi. 2014-Current Radiation Therapy Oncology Group (RTOG) (Principal Investigator for SCCA Proton Therapy Center RTOG Studies)

b. National: i. 2012-Current American Board of Radiology (ABR) (Member, Examiners,

Thoracic and Sarcoma Section) ii. 2008-Current American College of Radiology (Member, Lung Committee

Member, eData Committee) iii. 2002-Current American Society for Clinical Oncology (ASCO) (Member) iv. 2006-2008 American Brachytherapy Society (ABS) (Member) v. 2002-2006 American Medical Association (AMA) (Member)

vi. 2004-2006 American Radium Society (ARS) (Member)

10. Teaching Responsibilities: a. Courses:

i. Medical School, Cultural Competence Course, Fall 2008 1. Responsibilities: Shared small group biweekly didactic sessions with

medical students focusing on issues of cultural competency ii. Medical School, Doctoring I; Winter 2009- Fall 2009

1. Responsibilities: Shared small group biweekly didactic sessions with medical students focusing on issues related to professionalism and leadership in medicine. The goal is to preserve and promote humanism, multiculturalism and idealism in the pursuit of medical education, the cultivation of medical collegiality, and the development of the doctor-patient relationship

iii. Medical School, Doctoring II; Winter 2010- Fall 2010 1. Responsibilities: Shared small group biweekly didactic sessions with

medical students focusing on issues related to professionalism and leadership in medicine. The goal is to preserve and promote humanism, multiculturalism and idealism in the pursuit of medical education, the cultivation of medical collegiality, and the development of the doctor-patient relationship

iv. Medical School, Doctoring III; Winter 2011 1. Responsibilities: Shared small group biweekly didactic sessions with

medical students focusing on issues related to professionalism and leadership in medicine. The goal is to preserve and promote humanism, multiculturalism and idealism in the pursuit of medical education, the

cultivation of medical collegiality, and the development of the doctor-patient relationship

v. Medical School, Cultural Competence Course, Fall 2012 1. Responsibilities: Shared small group biweekly didactic sessions with

medical students focusing on issues of cultural competency vi. Resident Didactic Curriculum, University of Pennsylvania Thoracic Radiation

Oncology Course 2006-2013 1. Responsibilities: Developed resident teaching curriculum which includes

a one month comprehensive didactic block consisting of lectures, clinical case conferences, and clinical didactics

vii. Pulmonary Medicine Fellows Lung Cancer Course Spring 2007- Spring 2011 1. Didactic Lecture: “Radiotherapeutic management of non-small cell lung

cancer” viii. Nuclear Medicine Course 210, Department of Radiology, University of

Pennsylvania School of Medicine Fall 2008 1. Didactic Lecture: “Role of FDG-PET in the management of lung cancer”

ix. EPI 540 Seminar: Fred Hutchinson Cancer ResearchCenter (FHCRC) May 2014 1. “Cancer Biology and the Management of Lung Cancer”

x. Resident Didactic Curriculum, University of Washington Thoracic Radiation Oncology Course 2013-Current

1. Responsibilities: Developed resident didactic curriculum which includes a comprehensive didactic block consisting of lectures, clinical case conferences, and clinical didactics

a. Locally advanced NSCLC-Intro b. Locally advanced NCLC-Cases c. Extensive stage SCLC-Intro and Cases d. SCLC Cases

xi. Cancer Epidemiology and Biology Course: Fred Hutchinson Cancer Research Center (FHCRC) February 2014

1. “Cancer Biology and the Management of Lung Cancer”

b. Recent CME (last 5 years) i. April 2010 Functional Imaging in Radiotherapy Symposium,

University of British Columbia, Vancouver, BC “The role of functional imaging in the radiotherapeutic management of lung cancer”

ii. June 2010 World Conference on Interventional Oncology Philadelphia, PA “Lung cancer as a target for proton beam radiotherapy”

iii. June 2010 Symposium on PET/CT and Tomotherapy, Jeddah, Saudi Arabia “Application of functional imaging in lung cancer: Emerging concepts”

iv. June 2010 Symposium on Tomotherapy and Image Guided Radiotherapy, Riyadh, Saudi Arabia “The role of functional imaging in radiotherapy planning for non-small cell lung cancer”

v. September 2010 29th Annual Meeting of the European Society for Therapeutic Radiology, Barcelona, Spain “How PET/CT imaging can improve target delineation

for radiotherapy of lung cancer”

vi. September 2010 Cancer Center Grand Rounds, Oregon Health Sciences University, Portland, OR “The local control problem in locally advanced non-small cell lung cancer”

vii. October 2010 ASTRO Annual Meeting, San Diego, CA “Integration of functional imaging into the therapeutic paradigm for lung cancer”

viii. October 2010 13th Congress of the European Association of Nuclear Medicine Vienna, Austria

1. “Can functional imaging improve the therapeutic ratio for radiotherapy in lung cancer?”

2. “Expanding oncology care: Functional imaging for radiation treatment planning and quality assurance with Gemini time of flight big bore PET/CT”

ix. March 2011 Symposium of the Association of Indian Nuclear Medicine Physicians, Hotel Ramada Plaza, Delhi, India “Pulmonary functional imaging and its application to thoracic radiation oncology”

x. March 2011 Cancer Center Grand Rounds, Tata Memorial Hospital, Mumbai, India “The evolving role of functional imaging in radiation treatment planning for lung cancer”

xi. May 2011 Cancer Center Grand Rounds, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO “The impact of tumor biology on local control in NSCLC”

xii. May 2011 Fox Chase Cancer Center Thoracic Grand Rounds, Philadelphia, PA “Leveraging radiation and surgery to improve local control in non-small cell lung cancer”

xiii. July 2011 14th World Conference on Lung Cancer Amsterdam, NL “Adjuvant radiotherapy for thymoma”

xiv. December 2011 Annual Meeting of the Society of Nuclear Medicine- India, Chennai, Tamil Nadu, India “The Impact of PET/CT in Radiotherapy Planning for Lung Cancer”

xv. December 2011 Cancer Center Grand Rounds, Madras Medical College Chennai, Tamil Nadu, India “The role of Functional Imaging in Radiotherapy of Locally Advanced NSCLC and Head and Neck Cancer”

xvi. February 2012 Abramson Cancer Center Radiobiology and Imaging Symposium, University of Pennsylvania, Philadelphia, PA “A phase I/II trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for stage IIIA/IIIB NSCLC”

xvii. March 2012 4th Annual Saudi Nuclear Medicine Physicians Meeting, Istanbul, Turkey

1. “Functional imaging for radiation treatment planning”

2. “The impact of PET/CT in radiotherapy treatment planning for lung cancer”

xviii. April 2012 Cancer Center Grand Rounds, Henry Ford Hospital, Detroit, MI “Optimizing the therapeutic ratio for radiotherapy in locally advanced NSCLC”

xix. April 2012 IASLC Regional Symposium on Thoracic Oncology “Combined modality therapy for stage III NSCLC: Current status and future Directions”

xx. June 2012 Penn Radiation Oncology Clinical Trials Course, University of Pennsylvania, Philadelphia PA “Design of phase II clinical trials for radiotherapy”

xxi. September 2012 Abramson Cancer Center Radiobiology and Imaging Lecture Series, University of Pennsylvania, Philadelphia, PA “Radiosensitization with Nelfinavir in locally advanced NSCLC and an initial discussion of RADVAX- an emerging concept in radiotherapy”

xxii. September 2012 Multidisciplinary Symposium on Thoracic Oncology Chicago, IL “Integration of targeted therapies into chemo-radiotherapy for locally advanced NSCLC”

xxiii. October 2012 Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging, and Therapeutic Targets Crete, Greece “The tumor microenvironment as a target for the HIV Protease Inhibitor Nelfinavir in Stage IIIA/IIIB NSCLC: Early clinical trial results and interpretations”

xxiv. November 2012 Perspectives in Thoracic Oncology, New York, NY “Approaching Early Stage NSCLC: Surgery vs SBRT vs RFA”

xxv. December 2012 Tufts Cancer Center Grand Rounds, Boston, MA “Improving the therapeutic ratio for radiotherapy of locally advanced NSCLC”

xxvi. February 2013 Cancer Imaging and Radiotherapy Symposium Orlando, FL “Functional Imaging and Targeted Therapies in Locally Advanced NSCLC”

xxvii. March 2013 ASTRO Spring Refresher Course, Chicago, IL 1. “The Management of Lung Cancer” 2. “Critical Radiotherapeutic Clinical Alerts”

xxviii. October 2013 WCLC 2013 Sydney, Australia 1. “Targeted therapy and Stereotactic Body

Radiation Therapy” xxix. October 2013 New South Wales Cancer Center

1. Improving the therapeutic ratio in NSCLC: Role of particle beam therapy

xxx. February 2014 Melanoma Research Alliance Scientific Retreat

Washington, DC 1. “RADVAX: SBRT and Ipilimumab in

Metastatic Melanoma” xxxi. March 2014 ASTRO Spring Refresher Course, New Orleans, LA

1. “Critical Clinical Updates: Thoracic” 2. “The Management of Lung Cancer”

xxxii. April 2014 AACR Annual Meeting, San Diego, CA 1. “Protons and Carbon Ions to Improve the

Therapeutic Index of Radiation Therapy” xxxiii. April 2014 Bend, OR Outreach Meeting

1. “Radiotherapeutic Management of Non-Small Cell Lung Cancer: Where do we go from here?”

xxxiv. April 2014 ARS Annual Meeting, St. Thomas US Virgin Islands 1. “Challenging Lung Cases”

xxxv. June 2014 SCCA Solid Tumor Symposium, Seattle, WA 1. “Radiation Therapy: Emerging Applications in

Immunotherapy” xxxvi. August 2014 Oregon Health Sciences Department of Radiation

Medicine Grand Rounds, Portland, OR 1. “Improving the Therapeutic Ratio for Solid

Tumors: Is There a Role for Particle Beam Therapy?”

xxxvii. September 2014 ASTRO Annual Meeting, San Francisco CA 1. “Challenges and Solutions for Building a

Successful Career as a Physician Scientist in Radiation Oncology”

xxxviii. October 2014 Particle Therapy Group, North America Annual Meeting Houston, TX

1. “Proton Beam Radiotherapy in Thoracic Tumors: Future Directions”

xxxix. November 2014 Washington State Radiological Society Annual Meeting Kirkland, WA

1. “Best of ASTRO Annual Meeting: Thoracic Presentations”

xl. November 2014 FHCRC Immunotherapy Seminar Seattle, WA 1. “Emerging Applications for Radiotherapy in

Cancer Immunotherapy” xli. November 2014 Northwest Medical Center Grand Rounds Seattle, WA

1. “The Role of Proton Beam Radiotherapy in Solid Tumors: Opportunities and Challenges”

xlii. Mar 2015 Stanford University Department of Radiation Oncology Stanford, CA

1. “Can Particle Beam Therapy Improve the Therapeutic Window for NSCLC”

xliii. May 2015 American Radium Society, Kauai, HI 1. “The Role of Particle Beam therapy in Locally

Advanced NSCLC” xliv. Oct, 2015 ASTRO Annual Meeting, San Antonio, Texas

1. “Widening the Therapeutic Ratio for Radiotherapeutic Management of Locally

Advanced NSCLC: Particles, Tumor Biology, and Immune Modulation”

xlv. Oct, 2015 SCCA Symposium on Challenges and Controversies in Breast Cancer, Seattle, WA

1. “The Role of Protons in the Management of Locally Advanced Breast Cancer”

xlvi. Mar, 2016 2016 ASTRO Annual Refresher Course, La Jolla, CA 1. “Radiation Therapy Contraindications and

Safety Panel: Re-Irradiation, Novel Combination Therapies, and Hypofractionation”

c. Trainees/Mentorship i. 2008 Mentee: Christine Hill-Kayser, MD Medical Resident, Penn Radiation

Oncology 1. “Comparison of two methods for delivery of radiotherapy after

extrapleural pneumonectomy for treatment of mesothelioma” 2. “Creation of a windowing algorithm to accurately define tumor volume

and edge in PET Images in non-small cell lung cancer patients to guide treatment planning for radiotherapy”

ii. 2008 Mentee: Shalini Gargh, MD, Medical Student 3rd Year, Penn Medicine 1. “Patterns of failure after surgical resection of non-small cell lung cancer”

iii. 2008 Mentee: Annemarie Fernandes, Doris Duke Clinical Research Fellow, Penn 1. “Elective nodal irradiation vs. involved field radiotherapy for locally

advanced non-small cell lung cancer: Analysis of clinical outcomes” iv. 2009 Mentee: Andrew Trister, 3rd Year Medical Student, Penn Medicine

1. “Predictive factors on PET imaging to identify mediastinal nodal metastasis in non-small cell lung cancer”

v. 2009 Mentee: Abigail Berman, 3rd Year Medical Student, Penn Medicine 1. “Patterns of failure after surgical resection of thymoma”

vi. 2010 Mentee: Abi Orisamolu, ASCO Summer Research Fellow, 1st year medical student

1. “Predictive factors for symptomatic radiation penumonitis in 293 consecutively treated non-small cell lung cancer (NSCLC) patients receiving definitive radiation therapy”

vii. 2010 Mentee: Geoffrey Alan Geiger, MD, Medical resident, Penn Radiation Oncology

1. “Interscan progression on PET/CT in non-small cell lung cancer” viii. 2010 Mentee: Eric Xanthopoulos, MD JD, Research Fellow, Penn Radiation

Oncology 1. “Predictive factors for radiation pneumonitis” 2. “PCI for locally advanced NSCLC” 3. “Impact of PET on staging in small cell lung cancer” 4. “Definitive radiotherapy for oligometastatic NSCLC” 5. “PCI for extensive stage SCLC” 6. “Impact of therapeutic technique on toxicity for limited stage SCLC”

ix. 2011 Mentee: Katie Baratz, 4th year medical student 1. “Physician and societal biases towards the lung cancer patient”

x. 2011 Mentee: Abigail Berman, MD, Medical resident, Penn Radiation Oncology 1. “Dosimetric comparison of proton vs photon beam radiotherapy for post-

operative radiotherapy in locally advanced NSCLC” xi. 2011 Mentee: Genevieve Maquillan, 4th year medical student, Penn Med

1. “Relationship between response to chemotherapy and radiotherapy in locally advanced NSCLC”

xii. 2011 Mentee: Gita Suneja, MD, Medical resident, Penn Radiation Oncology 1. “Impact of HIV on treatment decision making in lung cancer”

xiii. 2011 Mentee: Aparna Kesarwala, Medical resident, NCI Radiation Oncology 1. “Proton beam radiotherapy for bilateral hilar involvement in locally

advanced NSCLC xiv. 2011 Mentee: Michael Corradetti MD PhD, Medical resident, Penn Radiation

Oncology 1. “IGRT parameters for SBRT of early stage NSCLC” 2. “PCI for locally advanced NSCLC”

xv. 2013 Mentee: Tom Mullen MD PhD, Medical resident, UW Radiation Oncology 1. “Molecular determinants of the radiation response in lung cancer”

xvi. 2013 Mentee: Tobias Chapman MD, Medical resident, UW Radiation Oncology 1. “Leukopenia and acute toxicity in chemoradiotherapy for lung cancer”

xvii. 2014 Mentee: Laura Kollar MD, Medical resident, UW Radiation Oncology 1. “SEER Analysis of patterns of failure in small cell carcinomas”

xviii. 2014 Mentee: Michael Gensheimer MD, Medical resident, UW Radiation Oncology

1. “Imaging predictors of response to cancer vaccines in breast cancer” xix. 2014 Mentee: Patrick Richard MD MPH, Medical resident, UW Radiation

Oncology 1. “Cost modeling for proton beam radiotherapy in solid tumors”

xx. 2015-2016 Clinical Faculty Mentee: Ralph Ermoian, MD,UW Radiation Oncology

xxi. 2015-2016 Academic/Clinical Faculty Mentee: Jing Zeng, MD, UW Radiation Oncology

xxii. 2015-2016 Faculty Mentee: Annemarie Fernandes Shepherd, MD, MSK Radiation Oncology

xxiii. 2015-2016 Faculty Mentee: Abigail Berman, MD, University of Pennsylvania Radiation Oncology

xxiv. 2015-2016 Faculty Mentee: Chuck Simone, MD, University of Pennsylvania Radiation Oncology

xxv. 2015-2016 Trainee: Shilpa Vyas, MD, University of Washington Department of Radiation Oncology

xxvi. 2015-2016 Trainee: Tobias Chapman, University of Washington Department of Radiation Oncology

11. Editorial Positions:

a. 2002-2006 Reviewer, Pediatric Blood & Cancer b. 2006-Current Reviewer, International Journal of Radiation Oncology, Biology,

and Physics c. 2008-Current Reviewer, Journal of Clinical Oncology d. 2008-Current Reviewer, Clinical Cancer Research e. 2008-Current Editorial Board, DEMOS Medical Publishing f. 2009-2010 Associate Guest Editor, Seminars in Radiation Oncology, Non-

Small Cell Lung Cancer and Pleural Malignancies g. 2011-Current Reviewer, Lancet h. 2011-Current Reviewer, Practical Radiation Oncology

12. Special National Responsibilities

a. 2015-Current ASTRO Blue Ribbon Panel Committee member b. 2015-Current Chair, Refresher Didactic Course, American Society for

Radiation Oncology (ASTRO) c. 2012-Current Written and Oral Board Examiner, Thoracic and Sarcoma

Section, American Board of Radiology (ABR) d. 2013-2015 Chair, IHE-RO Clinical Advisory Subcommittee e. 2011-2015 Translational Co-Chair, ASTRO Spring Refresher Course

Program Committee f. 2010-2015 Co-Chair, Planning Committee, Integration of the Health Care

Enterprise- Radiation Oncology (IHE-RO) g. 2010-2015 Member, Content Advisory Panel, RSNA h. 2011-2014 Thoracic Co-Chair, ASTRO Cancer Imaging and Radiation

Therapy Symposium, Program Committee i. 2010-2011 Vice-Chair, Publications Committee, American Society for

Radiation Oncology (ASTRO) j. Oct, 2006 Moderator, Scientific session on “PET and hypoxia in lung

cancer” American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Philadelphia, PA

k. Oct, 2007 Moderator, Scientific session on, “Stereotactic body radiotherapy and image guided radiotherapy in management of lung cancer” American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Los Angeles, CA

l. May, 2008 Moderator, Scientific session on, “Current Utilization of PET- CT in Radiation Oncology” PET-CT in Cancer Management: Current Perspectives at Penn, Sheraton University City Hotel, Philadelphia, PA

m. Oct, 2008 Moderator, Scientific session on, “Combined modality therapy and immunotherapy” The Eli Glatstein, MD Translational Research Conference on “New Paradigms in Oncology”, Ritz Carlton Hotel, Philadelphia, PA

n. Nov, 2008 Co-Chair, Medical Jeopardy Session Chicago Multidisciplinary Symposium in Thoracic Oncology, Marriott Hotel, Chicago, IL

o. Oct, 2009 Co-Chair, Focus on Lung Cancer Patient Symposium Hilton City Line Hotel, Philadelphia, PA

p. Nov, 2009 Moderator, Scientific sessions on lung cancer American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Chicago, IL

q. Oct, 2010 Co-Chair, Focus on Lung Cancer Patient Symposium Hilton City Line Hotel, Philadelphia, PA

r. Jul, 2011 Co-Chair, Update in Thoracic Oncology: Current Practices and Future Directions Continuing Medical Education Event, University of Pennsylvania Medical School, Philadelphia, PA

s. Oct, 2011 Co-Chair, Focus on Lung Cancer Patient Symposium Hilton City Line Hotel, Philadelphia, PA

t. Apr, 2012 Co-Chair, ASTRO Spring Refresher Course Westin Chicago River North, Chicago, Il

u. Oct, 2012 Co-Chair, Focus on Lung Cancer Patient Symposium Hilton City Line Hotel, Philadelphia, PA

v. Feb, 2013 Thoracic Program Co-Chair; Cancer Imaging and Radiation Therapy Symposium: A Multidisciplinary Approach

Hilton Orlando Lake Buena Vista in the Walt Disney World Resort Orlando, FL

w. Mar, 2013 Translational Co-Chair; ASTRO Spring Refresher Course JW Marriott Hotel, Chicago, IL

x. Mar, 2014 Translational Co-Chair; ASTRO Spring Refresher Course Roosevelt Hotel, New Orleans, LA

y. Sept, 2014 Faculty Co-Chair; ASTRO Annual Meeting Scientific Session “Community of Radiation Oncology Physician Scientists” San Francisco, CA

z. Oct, 2014 Member, Particle Therapy Group- North America Executive Committee

aa. Nov, 2014 Co-Chair National Symposium on; “Thoracic Malignancies: The Emerging role of Proton Beam Radiotherapy” Boulders Resort Hotel, Carefree, AZ

13. Special Local Responsibilities a. 2014-Current Member, Department of Radiation Oncology Advisory

Committee, Department of Radiation Oncology, University of Washington

b. 2013-Current NRG Institutional PI, SCCA Proton Therapy center c. 2006-2013 Member, Department of Radiation Oncology Faculty Search

Committee, University of Pennsylvania and Abramson Cancer Center

d. 2007-2013 Member, Clinical trials and scientific review committee, Abramson Cancer Center, Penn Medicine

e. 2007-2013 Department Lead, Tissue Banking and Biomarker Joint Initiative between the Department of Radiation Oncology at the University of Pennsylvania, Abramson Cancer Center and the Radiation Oncology Branch of the National Cancer Institute, Bethesda, MD

f. 2008-2013 Member, Abramson Cancer Center, Cancer Committee g. 2008-2013 Co-Chair, Abramson Cancer Center, Cancer Registry Data

Sub-Committee h. 2008-2013 Principal Investigator, Radiation Therapy Oncology Group and

direct liaison for the Department of Radiation Oncology, University of Pennsylvania

i. 2008-2012 Member, Doris Duke Clinical Research Fellowship Advisory Committee

j. 2009-2012 Radiation oncology departmental representative, UPHS electronic medical record EPIC governance committee

k. 2007-2011 Member, Educational Task Force, Department of Radiation Oncology, University of Pennsylvania and Abramson Cancer Center

l. 2007-2011 Faculty Member, House Staff Committee, Hospital of the University of Pennsylvania

m. 2007-2008 Department Lead, Bioinformatics Task Force, Department of Radiation Oncology, University of Pennsylvania and Abramson Cancer Center: Developed the department's strategic plan for data management and its integration.

n. 2008 Interim Department Lead; Stereotactic Radiosurgery Initiative;

Joint Initiative of the Radiation Oncology, ENT, and Neurosurgery Departments

14. Research Funding a. Current:

i. Multimodality Quantitative Molecular Imaging for Personalized Radiation Therapy of Lung Cancer through Differential Tumor Dose Escalation and Functional Lung Avoidance, 7/1/14-6/30/16 (Stephen Bowen, PI: Ramesh Rengan, Jing Zeng, Paul Kinahan, Matthew Nyflot, Robert Miyaoka, Hubert Vesselle, George Sandison, Shilpen Patel, Co-Investigators), $150,000/award amount (Role in grant: Consultant)

ii. RADVAX: Stereotactic Body Radiation Therapy with Ipilimumab in Melanoma, Melanoma Research Alliance Pilot Award, 7/2012-7/2014 (Ramesh Rengan, PI: Bob Vonderheide, Andy Minn, Co-Investigator), $50,000/annual direct costs, 5% effort (Role in grant: Principal Investigator)

iii. Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients with Metastatic Non-Small Cell Lung Cancer, STTR Pilot Award, 07/01/15-06/30/16 (Ramesh Rengan, PI), $54,000/annual amount

iv. Multimodality Quantitative Molecular Imaging for Personalized Radiation Therapy of Lung Cancer Through Differential Tumor Dose Escalation and Functional Lung Avoidance, 07/01/2014-06/30/2016, (Stephen Bowen, PI: Ramesh Rengan) $150,000 award amount (Role in grant: Co-Investigator)

v. Bezos Family Award vi. FLARE-RT RO1

b. Past: i. Discovery of Regulators and Biomarkers for RadVax, the Combination of

Radiation and Anti-CTLA4, for Metastatic Melanoma, Penn Radiation Oncology Pilot Funding Initiative, 10/2012-9/2013 (Andy Minn, PI: Ramesh Rengan, Co-Investigator), $25,000/annual direct costs (Role in grant: Co-PI, Pilot funding award for seed funds required in preparation for NIH submission)

ii. DCE-MRI for assessment of vascular normalization by nelfinavir in lung cancer, National Institute of Health (NIH) R21 Grant, 7/2010-6/2013 (Ramesh Rengan, PI: Mark A. Rosen, Co-Investigator), $250,000/annual direct costs, 15% effort (Role in grant: Principal investigator, NCE is approved through 6/30/13)

iii. Mechanisms and treatment of oligometastases, Department of Defense , 4/2009-3/2014 (Andy J. Minn, PI), $751,000/annual direct costs, 5% effort (Role in grant: Co-investigator)

iv. Prospective study of 18FDG uptake as an imaging biomarker of symptomatic radiation pneumonitis in patients with locally-advanced NSCLC treated with definitive radiotherapy, Thomas B. and Jeannete E. Laws McCabe Fund, 1/2009-6/2013 (Ramesh Rengan, PI), $24,421/annual direct costs (Role in grant: Principal investigator, Funds still active. Only using to support clinical trial)

v. Development of a multileaf collimator for proton radiotherapy, Department of Defense , 10/2008-10/2012 (James McDonough, PI), $2,509,137/annual direct costs, 10% effort (Role in grant: Sub-investigator)

vi. Inhibiting radiation resistance: Targeting the PI3-kinase/p-Akt signaling pathway using nelfinavir with concurrent thoracic chemoradiotherapy in locally advanced NSCLC , American Society for Therapeutic Radiology and Oncology, 7/2007-6/2013 (Ramesh Rengan, PI), $125,000/annual direct costs, 15% effort (Role in grant: Principal investigator, No cost extension approved through June 30, 2013. Remaining funds used for research support only and not salary support.)

vii. A prospective, multicenter trial to evaluate the efficacy of 18F-ML10, a PET imaging radiotracer, in early detection of response of non-hematological tumors to concurrent chemoradiotherapy, ApoSense Incorporated, 1/2011-12/2011 (Ramesh Rengan, PI: Dan Pryma, Alex Lin, Co-Investigator), $200,000/annual direct costs, 5% effort (Role in grant: Principle investigator)

viii. In vivo compatible readily injectable gold nanoconstructs for tumor therapy, National Institute of Health (NIH), National Cancer Institute (NCI), HHSN261201000100C, 9/2010-9/2012 (Wynn Volkert, PI: Anandhi Upendran, Co-Investigator), $814,346/annual direct costs, 1% effort (Role in grant: Sub-investigator)

ix. Protective role of flaxseed in radiation pneumonitis of lung cancer patients, Clinical and Translational Research Center, 9/2007-12/2009 (Ramesh Rengan, PI), $20,000/annual direct costs, 5% effort (Role in grant: Principal investigator)

15. Bibliography a. Manuscripts in referred journals

1. R. Rengan, P.K. Chakraborty, M.R. Kilbourn: Can we predict reactivity for aromatic nucleophilic substitution with [18F] fluoride ion? Journal of Labelled Compounds and Radiopharmaceuticals 33: 563-72, July 1993.

2. Rapid Oscillations of Actin Polymerization/Depolymerization in Polymorphonuclear Leukocytes Stimulated by Leukotriene B4 and Platelet Activating Factor. G.M. Omann, R. Rengan, J.F. Hoffman, J.J. Linderman: Journal of Immunology 155(11): 5375, 1995 December. PubMed PMID: 7594553

3. R. Rengan: Signaling actin polymerization responses in hematopoietic cells. Doctoral Dissertation, University of Michigan Medical School August 1998.

4. Regulation of Oscillations in Filamentous Actin Content in Polymorphonuclear Leukocytes Stimulated with Leukotriene B4 and Platelet Activating Factor: R. Rengan, G.M. Omann: Biochemical and Biophysical Research Communications 262: 479-86, 1999 August. PubMed PMID: 10462500

5. Actin Cytoskeletal Function is Spared, But Apoptosis is Increased in WAS Patient Hematopoietic Cells. R. Rengan, H.D. Ochs, L.I. Sweet, M.L. Keil, W.T. Gunning, N.A. Lachant, L.A. Boxer, G.M. Omann:. Blood 95: 1282-92, 2000 February. PubMed PMID: 10666201

6. Molecular Biology of the Wiskott-Aldrich Syndrome: R. Rengan, H.D. Ochs:. Reviews in Immunogenetics 2: 243-55, 2000. PubMed PMID: 11258421

7. Improved Local Control with Higher Doses of Radiation in Large Volume Stage III Non-Small Cell Lung Cancer. R. Rengan, K.E. Rosenzweig, E.S. Venkatraman, L.A. Koutcher, J.L. Fox, R. Nayak, H. Amols, E. Yorke, A. Jackson, C.C. Ling, S.A. Leibel: International Journal of Radiation Oncology • Biology • Physics 60(3): 741 - 7, 2004 November. PMID: 15465190

8. Does the Registration of FDG-PET and Planning CT Images Decrease Interobserver and Intraobserver Variation in Delineating Tumor Volumes for Non-Small Cell Lung Cancer (NSCLC)? J.L. Fox, R. Rengan, W.P. O'Meara, E. Yorke, Y. Erdi, S. Nehmeh, S. Leibel, K.E. Rosenzweig: International Journal of Radiation Oncology • Biology • Physics 62(1): 70-5, 2005 May. PubMed PMID: 15850904

9. Distal cT2N0 rectal cancer - Is There an Alternative to Abdominoperineal Resection? R. Rengan, P. Paty, W.D. Wong, J. Guillem, M. Weiser, L. Temple, L. Saltz, B.D. Minsky: Journal of Clinical Oncology 23(22): 4905-12, 2005 August. PubMed PMID: 16051945

10. Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. R. Rengan, P.B. Paty, W.D. Wong, J.G. Guillem, M. Weiser, L.Temple, L. Saltz, B.D. Minsky:. Clinical Coloractal Cancer v5 n6 413-421 2006 Mar PubMed PMID: 16635280

11. Clinical Target Promiscuity: Lessons From Ras Molecular Trials Cancer and Metastasis Reviews.R. Rengan, K.A. Cengel, S.M. Hahn: Rob Bristow (eds.). 2008 September. PubMed PMID: 18461427

12. Long-Term Neck Control Rates After Complete Response to Chemoradiation in Patients with Advanced Head and Neck Cancer. R. Rengan, D.G. Pfister, N.Y. Lee, D.H. Kraus, J.P. Shah, A.R. Shaha, L.S. Ben-Porat, M.J. Zelefsky American Journal of Clinical Oncology 31(5): 465-469, 2008 October PubMed PMID: 18838883

13. New Approaches to Radiotherapy as Definitive Treatment for Inoperable Lung Cancer. A.T. Berman, R. Rengan: Seminars in Thoracic and Cardiovascular Surgery 2008 November. PubMed PMID: 19038727

14. Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Tale of Two Techniques C.E. Hill-Kayser, S. Avery, C.F. Mesina, P. James, J.S. Friedberg, K.A. Cengel, L.L. Lin, S.M. Hahn, R. Rengan Journal of Thoracic Oncology 2009 November. PMCID: 19745767

15. Radiotherapy for Eyelid, Periocular, and Periorbital Skin Cancers. A.T. Berman, R. Rengan, P. Tripuraneni: International Opthalmology Clinics 49(4): 129-142, 2009. PubMed PMID: 20203540

16. Integrating the Healthcare Enterprise in Radiation Oncology (IHE-RO)Plug and Play - The Future of Radiation Oncology? M. Abdel-Wahab, R. Rengan, B. Curran, S. Swerdloff, M. Mittinen, C. Field, S. Ranjitkar, J. Palta, P. Tripuraneni: International Journal of Radiation Oncology • Biology • Physics 76(2): 333-336, 2010 February. PubMed PMID: 20117286

17. Elective Nodal Irradiation (ENI) vs. Involved Field Radiotherapy (IFRT) for Locally Advanced Non-Small Cell Lung Cancer (NSCLC): A Comparative Analysis of Toxicities and Clinical Outcomes. A.T. Fernandes, T.L. Evans, J. Stevenson, C.J. Langer, N. Mitra, E.J. Glatstein, S.M. Hahn, L. L. Lin, R. Rengan: Radiotherapy and Oncology J. Overgaard (eds.). 95(2): 178-184, 2010 May. PubMed PMID: 20356642

18. Adjuvant Cisplatin and Cocetaxel (CDDP-Doc) for Non-Small Cell Lung Cancer (NSCLC): The Hospital of the University of Pennsylvania (HUP) Experience. J.Weiss, B. Eaby, J. Stevenson, J. Kucharczuk, J. Cooper, L. Kaiser, J. Shrager, R. Rengan, C. Langer, T. Evans : Journal of Thoracic Oncology 5(5): 667-672, 2010 May. PubMed PMID: 20234321

19. Non-Small Cell Lung Cancer and Pleural Malignancies: The End of the Era of Therapeutic Nihilism? R. Rengan, S.M. Hahn. Seminars in Radiation Oncology J. Tepper (eds.). 20(3): 147-148, 2010 July PubMed PMID: 20685576

20. The Role of Radiation Therapy in Malignant Thymoma: A SEER Database Analysis. A.T. Fernandes, E.T. Shinohara, M. Guo, N. Mitra, L.D. Wilson, R. Rengan, J.M. Metz : Journal of Thoracic Oncology 5(9): 1454-60, 2010 September. PubMed PMID: 20651611

21. Extrapleural Pneumonectomy, Photodynamic Therapy and Intensity Modulated Radiation Therapy for the Treatment of Malignant Neoplasms of the Thorax Involving the Pleura. Cancer Biology and Therapy Wafik El-Deiry (eds.). 10(5): 425-429, 2010 September. PubMed PMID: 20699634

22. New Strategies in Non-Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. R. Rengan, A.M. Maity, J.P. Stevenson, S.M. Hahn: Clinical Cancer Research May 2011. PubMed PMID: 21576083

23. A Glimpse of the Future: Where Will New Combinations of Diagnostics and Therapies Take Us? M.A. Basanta, C. Chapman, J.F. Dorsey, R. Rengan, S. M. Hahn: The Cancer Journal 17(2): 190-194, 2011 June PubMed PMID: 21610473

24. Adjuvant Radiotherapy for Completely Resected Stage 2 Thymoma. Cancer A.T. Berman, L. Litzky, V. Livolsi, S.Sunil, J.C. Kucharczuk, J.D. Cooper, J.R. Friedberg, T.L. Evans, J.P. Stevenson, J.M. Metz, S.M. Hahn, R. Rengan: 117(15): 3502-8, 2011 August. PubMed PMID: 21287527

25. Addressing Connectivity Issues: The Integrating the Healthcare Enterprise-Radiation Oncology (IHE-RO) Initiative. R. Rengan, B. Curran, C. Able, M. Abdel-Wahab, A. Ravi, K. Albuquerque, C. Field, S. Abdul, R. Kapoor, P. Tripuraneni, J. Palta: Practical Radiation Oncology W. Robert Lee (eds.). 2011 August. PubMed PMID: 24674000

26. Effect of Body Mass Index on Magnitude of Setup Errors in Patients Treated with Adjuvant Radiotherapy for Endometrial Cancer with Daily Image Guidance. L.L. Lin, L. Hertan, R. Rengan, B.K. Teo: International Journal of Radiation Oncology • Biology • Physics 83(2) 670-675, 2011 December. PubMed PMID: 22208974

27. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy (CT-RT) for Unresectable Stage IIIA/IIIB NSCLC: A Report of Toxicities and Clinical Response. R. Rengan, R. Mick, D. Pryma, M.A. Rosen, L. Lin MD, A. Maity MD PhD, T. L. Evans MD, J. P. Stevenson MD, C.J. Langer MD, J. Kucharczuk MD, J. Friedberg MD, S. Prendergast RN, T. Sharkoski BA, and S.M. Hahn MD : Journal of Thoracic Oncology 7(4): 709-715, April 2012. PubMed PMID: 22425919

28. The Impact of Extent and Location of Mediastinal Lymph Node Involvement on Survival in Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Definitive Radiotherapy. A.T. Fernandes, N. Mitra, E. Xanthopoulos, T.L. Evans, J.P. Stevenson, C.J. Langer, J. Kucharczuk, L. Lin, R. Rengan. International Journal of Radiation Oncology • Biology • Physics 83(1): 340-7, 2012 May. PubMed PMID: 22104359

29. Definitive Radiotherapy for Unresected Adenoid Cystic Carcinoma of the Trachea. Chest L.P. Bonner Millar, D.L. Stripp, P. James, S. Both, J.D. Cooper, R. Rengan: 141(5): 1323-1326, 2012 May. PubMed PMID: 22553266

30. Predicting Radiation Pneumonitis after Chemoradiotherapy for Lung Cancer: An International Individual Patient Data Meta-analysis. D. Palma, S. Senan; K. Tsujino; R.B. Barriger; R. Rengan; M. Moreno; J.D. Bradley; T. H. Kim; S. Ramella; L.B. Marks; L. De Petris; L.Stitt; G. Rodrigues: International Journal of Radiation Oncology, Biology, Physics 2012 June. PubMed PMID: 22682812

31. Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated with Definitive Radiation: Dosimetric Analysis and Clinical Implications. M.J. Eblan, M.N. Corradetti, J.N. Lukens, E. Xanthopoulos, N. Mitra, J.P. Christoudouleas, S. Grover, A.T. Fernandes, C.J. Langer, T.L. Evans, J.P. Stevenson, R. Rengan, S. Apisarnthanarax: International Journal of Radiation Oncology, Biology, Physics 2012 June. PubMed PMID: 22658442

32. Central Airway Necrosis after Stereotactic Body Radiation Therapy. M.N. Corradetti, A. Haas, R. Rengan: New England Journal of Medicine 366(24): 2327-2329, 2012 June. PubMed PMID: 22694017

33. Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Lin L. L, Silvoniemi Antti, Stubbs J.B., Rengan R., Suilamo S., Solin O., Divgi C., Eskola O., Sorger J. M., Stabin M. G., Kachur A., Hahn S. M., Grönroos T. J., Forsback S., Evans S. M., Koch C.J., Minn H. : Cancer Biotherapy & Radiopharmaceuticals 27(7): 412-9, 2012 August. PubMed PMID: 22897720

34. Inhibition of Autophagy as a Strategy to Augument Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235. G. J. Cerniglia, J. Karar, S. Tyagi, M.Christofidou-Solomidou, R. Rengan, C. Koumenis, Amit Maity: Molecular Pharmacology 2012 September. PubMed PMID: 22989521

35. Prognostic Value of Primary Tumor FDG Uptake for Occult Mediastinal Lymph Node Involvement in Clinically N2/N3 Node Negative Non-Small Cell Lung Cancer. A. D. Trister; D. A. Pryma; E. Xanthopoulos; J. Kucharczuk; D. Sterman; R. Rengan: American Journal of Clinical Oncology 2012 October. PubMed PMID: 23111361

36. Impact of HIV Infection on Survival in Non-Small Cell Lung Cancer Patients in the Era of Highly Active Anti- Retroviral Therapy: A Population-Based Analysis. R. Rengan, N. Mitra, K. Liao, K. Armstrong, A. Vachani: Lancet Oncology 13(12): 1203-9, 2012 December. PubMed PMID: 23164952

37. Disparities in the Treatment and Outcomes of Lung Cancer Among HIV-Infected Individuals. G. Suneja, M. S. Shiels, S. K. Melville, M. A. Williams, R. Rengan, E. A. Engels: AIDS 2013 January. PubMed PMID: 23079809

38. Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated with Definitive Radiation: Dosimetric Analysis and Clinical Implications. M. J. Eblan, M. N. Corradetti, J. N. Lukens, E. Xanthopoulos, N. Mitra, J. P. Christodouleas, S. Grover, A. T. Fernandes, C.J. Langer, T. L. Evans, J. Stevenson, R. Rengan, S. Apisarnthanarax: Int J Radiat Oncol Biol Phys. 2013 Jan. PubMed PMID: 22658442

39. A.H. Kesarwala, S. Grover, R. Rengan: Role of Particle Beam Therapy in a Trimodality Approach to Locally Advanced Non-Small Cell Lung Cancer. Thoracic Cancer, v4, issue 2, p 95-101, May 2013

40. Stereotactic Body Radiation Therapy for Lung Cancer..B. Simone, B. Wildt, A.R. Haas, G. Pope, R. Rengan, S.M. Hahn Chest 2013 Jun;143(6):1784-90. PubMed PMID: 23732589

41. An In-Silico Comparison of Proton Beam and IMRT for Postoperative Radiotherapy in Completely Resected Stage IIIA Non-Small Cell Lung Cancer. A.T. Berman, B.K.Teo, D. Dolney, S. Swisher-McClure, K. Shahnazi, S. Both, R. Rengan: Radiat Oncol. 2013 Jun 15; p144. PubMed PMID: 23767810

42. Impact of PET Staging in Limited Stage Small Cell Lung Cancer. E. Xanthopoulos, M.N. Corradetti, N. Mitra, A.T. Fernandes, M. Kim, S. Grover, J.P Christodouleas, T.L. Evans, J.P. Stevenson, C.J. Langer, T.T. Lee, D.A. Pryma, L.L. Lin, C.B. Simone, S. Apisarnthanarax, R. Rengan: J. Thorac. Oncol. 2013 July. PubMed PMID: 23608814

43. High Body Mass Index is Associated with Worse Quality of Life in Breast Cancer Patients Receiving Radiotherapy. Breast Cancer Res Treat. P Fang, K.S. Tan, A.B. Troxel, R. Rengan, G. Freedman, L.L. Lin: 2013 Aug;141(1):125-33. PubMed PMID: 23942874

44. Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation .A.T. Berman, J. Turowski, R. Mick, K. Cengel, N. Farnese, L. Basel-Brown, C. Mesaros, I. Blair, J. Lawson, M. Christofidou-Solomidou, J. Lee, R. Rengan. Jrnl Pulm Repir Med 2013 August. PubMed PMID: 24575360

45. A Moving Target: Image Guidance for Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. M. N. Corradetti, N. Mitra,L.P. Bonner-Millar, J. Byun, F.Wan, S. Apisarnthanarax, J.Christodouleas, N. Anderson, C.B. Simone II, B.K. Teo, R.Rengan. Practical Radiation Oncology 2013 Oct. PubMed PMID: 2464403

46. Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis. D. Palma, S. Senan, C. Oberije, J. Belderbos, N.R. Dios, J.D. Bradley, R.B. Barriger, M. Moreno-Jiménez, T.H. Kim, S. Ramella, S. Everitt, R. Rengan, L.B. Marks, K. De Ruyck, A. Warner, G. Rodrigues: Int J Radiat Oncol Biol Phys. 2013 Nov. PubMed PMID: 24035329

47. Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate. Lin L, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR. Oncol Lett. 2014 Apr;7(4):1151-1158. Epub 2014 Feb 5. PubMed PMID: 24944684

48. Impact of Sociodemographic Factors on the Radiotherapeutic Management of Lung Cancer: Results of a Quality Research in Radiation Oncology Survey. R. Rengan, A. Ho, J.B. Owen, R Komaki, N Khalid, J F Wilson, B. Movsas: Pract Rad Onc 2014 May-Jun;4(3):e167-79. Doi 10.1016/j.prro.2013.07.012. PubMed PMID: 24766691

49. International Outreach: What is the Responsibility of ASTRO and the Major International Radiation Oncology Societies? Mayr NA, Hu KS, Liao Z, Viswanathan AN, Wall TJ, Amendola BE, Calaguas MJ, Palta JR, Yue NJ, Rengan R, Williams TR. Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):481-4. doi: 10.1016/j.ijrobp.2013.12.052. Pub Med PMID:24929158

50. Combination of Stereotactic Ablative Body Radiation with Targeted Therapies. Zeng J, Baik C, Bhatia S, Mayr N, Rengan R. Lancet Oncol. 2014 Sep;15(10):e426-e434. doi: 10.1016/S1470-2045(14)70026-9. Review. PMID:25186046

51. G.A. Geiger, E. P. Xanthopoulos, M. B. Kim, D.A. Pryma, S. Grover, J. P. Plastaras, C. J. Langer, C. B. Simone, R. Rengan: Stage Migration In Planning PET/CT Scans In Patients Due to Receive Radiation (XRT) for Non-small Cell Lung Cancer. Clin Lung Cancer 2014;15(1):79-85

52. Dynamic Simulation of Motion Effects in IMAT Lung SBRT. Wei Zou Lingshu, Yin Jiajian, Shen Michael, N Corradetti, Maura Kirk, Reshma Munbodh, Penny Fang, Salma K Jabbour, Charles B Simone II, Ning J Yue, Ramesh Rengan, Boon-Keng Kevin Teo. Radiation Oncology Journal MS: 4728769281345632 2014 Nov 1; p225

53. The role of proton beam radiotherapy in the management of thoracic malignancies. C. Simone and R. Rengan. Cancer Journal 2014 Nov-Dec;20(6):427-32

54. Stereotactic Body Radiation Therapy. Seminars in Oncology. L. Kollar and R. Rengan. 2014 Dec;41(6)776-789

55. Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience.S. Chawla, S. Wang, S. Kim, S. Sheriff, P. Lee, R. Rengan, A. Lin, E. Melhem, A. Maudsley, H. Poptani.

J Neuroimaging. 2015 Jan-Feb;25(1):97-104. doi: 10.1111/jon.12070. Epub 2013 Nov 26. PMID: 24279509

56. Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Victor CT, A.J. Rech, A. Maity, R. Rengan, K.E. Pauken, E. Stelekati, J.L. Benci, B. Xu, H. Dada, P.M. Odorizzi, R.S. Herati, K.D. Mansfield, D. Patsch, R.K. Amaravadi, L.M. Schuchter, H. Ishwaran, R. Mick, D.A. Pryma, X Xu, M.D. Feldman, T.C. Gangadhar, S.M. Hahn, E.J. Wherry, R.H. Vonderheide and A.J. Minn. Nature 2015 March 9: doi: 10:1038/nature 14292. PubMed PMID: 25754329

57. Intensity-Modulated Proton Therapy for Elective Nodal Irradiation and Involved-Field Radiation in the Definitive Treatment of Locally Advanced Non-Small Lung Cancer: A Dosimetric Study. Clin Lung Cancer. A.H. Kesarwala, C.J. Ko, H. Ning, E. Xanthopoulos, K.E. Haglund, W.P. O'Meara, C.B. Simone 2nd and R. Rengan. 2014 Dec 9.pii: S1525-7304(14)00318-X. doi: 10.1016/j.clic.2014.12.001. PubMed PMID:25604729

58. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, DeRuyck K, De Dios NR, Warner A, Bradley JD, Palma DA. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115. PubMed PMID: 2583522

59. Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. Berman AT, James SS, Rengan R. Cancers (Basel). 2015 Jul 2;7(3):1178-90. doi: 10.3390/cancers7030831. Review. PubMed PMID: 26147335

60. Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. Xanthopoulos EP, Handorf E, Simone CB 2nd, Grover S, Fernandes AT, Sharma S, Corradetti MN, Evans TL, Langer CJ, Mitra N, Shah A, Apisarnthanarax S, Lin LL, Rengan R. Pract Radiat Oncol. 2015 Jul-Aug;5(4):e355-63. doi: 10.1016/j.prro.2014.11.006. Epub 2015 Jan 31. PubMed PMID: 25649540

61. Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations. Grover S, Chadha M, Rengan R, Williams TR, Morris ZS, Morgan DA, Tripuraneni P, Hu K, Viswanathan AN. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):957-60. doi: 10.1016/j.ijrobp.2015.08.009. Epub 2015 Aug 7. PubMed PMID: 26581132

62. Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. Chvetsov AV, Sandison GA, Schwartz JL, Rengan R. Phys Med Biol. 2015 Nov 7;60(21):8491-503. doi: 10.1088/0031-9155/60/21/8491. Epub 2015 Oct 20. PubMed PMID: 26485348

63. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.  Warner A, Dahele M, Hu B, Palma DA, Senan S, Oberije C, Tsujino K, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, De Ruyck K, De Dios NR, Bradley JD, Rodrigues G. Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):612-20. doi: 10.1016/j.ijrobp.2015.11.030. Epub 2015 Nov 23. PubMed PMID:

64. Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment. G. Maquilan, S. Grover, E. Xanthopoulou, T. Evans, C.

Aggarwal, C. Langer, R. Cohen, J. Stevenson, C. Simone 2nd, R. Rengan; Am J Clin Oncol. 2016 April 20. [Epub ahead of print] PMID: 27100960

65. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. J. Chang, D De Ruysscher, SE Schild, CB Simone 2nd, R. Rengan, S. Feigenberg, A. Khan, N. Choi, J. Bradley, X. Zhu, A. Lomas, B. Hoppe; International Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee. Int J Radiat Oncol Biol Phys. 2016 May 1:95(1):505-16. Doi: 10.1016/j.ijrobp.2016.01.036. Epub 2016 Jan 23. Review. PMID: 27084663

66. Oligometastatic NSCLC: Current treatment strategies. P. J. Richard and R. Rengan. Lung Cancer: Targets and Therapy. 2016 (in press)

b. Book chapters

1. R. Rengan, C. Thomas: Thymoma and thymic carcinoma. Encyclopedia of Radiation Oncology. L. Brady, T.E. Yaeger (eds.). Springer-Verlag, 2010.

2. R. Rengan, C. Thomas: Non-myxomatous primary cardiac tumors. Encyclopedia of Radiation Oncology. L. Brady, T.E. Yaeger (eds.). Springer-Verlag, 2010.

3. R. Rengan, C. Thomas: Mediastinal germ cell tumors. Encyclopedia of Radiation Oncology. L. Brady, T.E. Yaeger (eds.). Springer-Verlag, 2010.

4. R. Rengan, C. Thomas: Pleural mesothelioma. Encyclopedia of Radiation Oncology. L. Brady, T.E. Yaeger (eds.). Springer-Verlag, 2010.

5. S.H. Lin, R. Rengan: Hemangiopericytoma. Radiation oncology: A question-based review. B. Hristov, S. Lin, J. Christodouleas (eds.). Lippincott, Williams and Wilkins, 2010.

6. R. Rengan, L.P. Bonner-Millar, C.R. Thomas: Uncommon thoracic tumors. Clinical Radiation Oncology. L.G. Gunderson, J.T. Tepper (eds.). Elsevier, 2012.

7. R. Rengan, I. Chetty, R. Decker, C.J. Langer, W.P. O'Meara, B. Movsas: Thoracic Oncology: Lung. Perez and Brady's Principles and Practice of Radiation Oncology. Lippincott Williams and Wilkins, 2013.

8. R. Rengan, D. Stripp, E. Glatstein: Radiation complications. Hematology-Oncology Therapy (in press). M.M. Boyiadzis, P.F. Lebowitz, J.N. Frame, T. Fojo (eds.). McGraw-Hill Professional, 2013.

9. C. Deville, G. Shukla, R. Rengan, C. Thomas: Radiotherapy. American Cancer Society Textbook of Cancer (in press). T. Gansler (ed), Wiley, (in press)

10. J. Zeng, R. Rengan, C. Thomas: Uncommon thoracic tumors. Clinical Radiation Oncology. J. Bogart. L.G. Gunderson, J.T. Tepper (eds.). Elsevier, (in press)

c. Published books, videos, software: none

d. Other publications: none

e. Manuscripts submitted

f. Abstracts (select) 1. R. Rengan, M.R. Kilbourn: Can we predict reactivity for aromatic nucleophilic

substitution with [18F]fluoride ion? Journal of Labelled Compounds and Radiopharmaceuticals 32: 99-100, 1992.

2. R. Rengan, G.M. Omann: Signaling mechanisms involved in producing the oscillating actin polymerizations/depolymerization response in human polymorphonuclear leukocytes. Biennial Arthritis Research Conference Meeting Proceedings May 1996.

3. R. Rengan, G.M. Omann: Regulation of oscillating actin polymerization/depolymerization in neutrophils. Journal of Leukocyte Biology S(1): 13, 1998.

4. R. Rengan, H.D. Ochs, M.L. Keil, L.I. Sweet, C. Watanabe, Q. Zhu, E.P. Calomeni, W.T. Gunning, N.A. Lachant, G.M. Omann: The role of Wiskott-Aldrich syndrome protein in signaling cytoskeletal remodeling. Pediatric Research 43(4): 137A, 1998.

5. R. Rengan, L.I. Sweet, M.L. Keil, N.A. Lachant, H.D. Ochs, G.M. Omann: Apoptosis is accelerated in Wiskott-Aldrich syndrome lymphocytes. Experimental Biology Annual Meeting Proceedings 1998.

6. J.L. Fox, K.E. Rosenzweig, R. Rengan, W.P. O'Meara, E. Yorke, Y. Erdi, S. Nehmeh, S. Leibel: Does the registration of FDG-PET and planning CT images decrease inter- and intra-observer variation in delineating tumor volumes for non-small cell lung cancer (NSCLC)? International Journal of Radiation Oncology • Biology • Physics October 2004.

7. R. Rengan, K.E. Rosenzweig, E.S. Venkatraman, E. Yorke, C.C. Ling, S.A. Leibel: Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. The Cancer Journal 10(S1): 36, 2004 Notes: (Presented May 2004, Napa Valley, CA).

8. R. Rengan, P. Paty, W.D. Wong, J. Guillem, M. Weiser, B.D. Minsky: Sphincter preservation with preoperative external beam radiotherapy and coloanal anastomosis in rectal cancer: 10-year follow up of functional and oncologic outcome. American Radium Society Meeting Proceedings 2005 Notes: (Presented at the American Radium Society Annual Meeting, May 2005, Barcelona, Spain).

9. R. Rengan, P. Paty, W.D. Wong, J. Guillem, M. Weiser, L. Temple, L. Saltz, B.D. Minsky: Distal cT2N0 rectal cancer - Is there an alternative to abdominoperineal resection? Journal of Clinical Oncology Annual Meeting Proceedings 2005 Notes: (Presented May 2005, Orlando, FL).

10. R. Rengan, D. Pfister, N. Lee, D. Kraus, J. Shah, A. Shaha, L. Ben Porat, M. Zelefsky: Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer International Journal of Radiation Oncology • Biology • Physics 66(3): S17, October 2006.

11. R. Rengan, D. Pfister, N. Lee, D. Kraus, J. Shah, A. Shaha, L. Ben Porat, M. Zelegsky: Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer. Multidisciplinary Head and Neck Cancer Symposium Meeting Proceedings Jan 2007.

12. C. Hill-Kayser, S. Avery, P. James, C.F. Mesina, J.S. Friedberg, L.L. Lin, S.M. Hahn, R. Rengan: Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: A tale of two techniques. International Journal of Radiation Oncology • Biology • Physics 69(3): S502, October 2007.

13. P. Tripuraneni, J. Palta, B. Curran, C. Field, M. Abdel-Wahab, M. Miettinen, S. Swerdloff, R. Rengan, S. Ranjitkar : The integrating the healthcare enterprise - radiation oncology (IHE-RO) initiative. Annual Meeting Proceedings: Royal Australian and New Zealand College of Radiologists October 2008.

14. A. Berman, S. Singhal, S. Su, J. Kucharczuk, J. Cooper, J. Shrager, L. Kaiser, J. Friedberg, J. Faerber, T. Evans, J. Stevenson, C.J. Langer, J. Metz, E. Glatstein, S.M. Hahn, R. Rengan: Adjuvant radiotherapy for completely resected stage II thymoma. Journal of Thoracic Oncology 2009.

15. A. Fernandes, J. Faerber, B. Eaby, T. Evans, J. Stevenson, C.J. Langer, L.Lin, E. Glatstein, S.M. Hahn, R. Rengan: The impact of, extent and location of mediastinal lymph node (LN) involvement on survival of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy. Journal of Thoracic Oncology 2009.

16. A. Trister, C. Gillespie, A. Haas, D. Sterman, J. Kucharczuk, J. Cooper, J. Friedberg, J. Wobb, T. Lucas, D. Pryma, C. Divgi, L. Lin, R. Rengan : Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in N2 node negative non-small cell lung cancer as staged by positron emission tomography. Journal of Thoracic Oncology 2009.

17. A. Trister, D. Pryma, R. Rengan, L. Lin, S. Hahn, A. Alavi, C. Divgi: Does the addition of a second PET image aid the diagnosis of non-small cell lung cancer? A single institution experience of 1889 studies. Journal of Thoracic Oncology 2009

18. J. Weiss, B. Eaby, J. Stevenson, J. Kucharczuk, J. Cooper, L. Kaiser, J. Shrager, R. Rengan, C. Langer, T. Evans: Adjuvant cisplatin and docetaxel (CDDP-Doc) for non-small cell lung cancer (NSCLC): the Hospital of the University of Pennsylvania (HUP) experience. Journal of Thoracic Oncology 2009.

19. R. Rengan, R. Mick, L. Lin, A. Maity, A. Gupta, T. Evans, J. Stevenson, C.J. Langer MD, J. Kucharczuk, J. Friedberg, S. Prendergast, J. Driesbaugh, S.M. Hahn: Early results of a phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for Stage IIIA/IIIB NSCLC. Journal of Thoracic Oncology 2009.

20. A.T.Berman, K. Teo, K. Shahnazi, R. Rengan: A dosimetric comparison of double-scattering proton beam versus IMRT photon beampost-operative radiotherapy for completely resected IIIA non-small cell lung cancer Chicago Multidisciplinary Symposium in Thoracic Oncology Meeting Proceedings December 2010.

21. M. Corradetti; K. Teo, N. Anderson, C. Barlow, R. Rengan: The accuracy of orthogonal KV matching to bony anatomy for patient positioning in patients receiving stereotactic body radiation therapy for early-stage non-small cell lung cancer. Chicago Multidisciplinary Symnposium in Thoracic Oncology Meeting Proceedings December 2010.

22. E.P. Xanthopoulos, A.T. Fernandes, S. Apisarnthanarax, J. Christodouleas, B. Eaby-Sandy, C.J. Langer, T.L. Evans, L. Lin, S.M. Hahn, R. Rengan: Definitive dose thoracic radiotherapy in oligometastatic stage IV non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2011 PMID: 25649540

23. G.A. Geiger, M.B. Kim, J.P. Plastaras, R. Rengan: Rapid disease progression in non-small cell lung cancer patients previously staged with PET/CT. Journal of Thoracic Oncology 2011.

24. M. Corradetti, K. Teo, L. Bonner, R. Rengan: A moving target: Image guidance for stereotactic body radiation therapy. Journal of Thoracic Oncology 2011.

25. R. Rengan, N. Mitra, K.J. Liao, I. Frank, K. Armstrong, A. Vachani: Impact of HIV infection on survival in lung cancer: A SEER-Medicare analysis. Journal of Thoracic Oncology 2011.

26. Y. Xue, J. Yu, M.A. Rosen, R. Rengan, H.S. Kang, S. Englander, R. Mick, and H.K. Song: Enhanced perfusion measurement accuracy in DCE-MRI via improved baseline signal estimation. Proceedings of the International Society for Magnetic Resonance in Medicine 2011.

27. J. Zou, L. Yin, J. Shen, M. Corradetti, M. Kirk, R. Rengan, B.K. Teo: The Effect of Motion in Rapid/Arc Lung SBRT Delivery. Medical Physics 39, 3611 2012.

28. S. Tang, L. Yin, R. Rengan, P. James, S. Hahn, S. Both: Interfractional Dosimetric Verification of Lung Patients Treated by Passive Double Scattering Proton Radiotherapy. Medical Physics 39, 3805 2012

29. A. Caringi, B. Goldsmith, M. Kirk, S. Both, R. Rengan, C. Simone, J. Christodouleas: Combined Photon SBRT and Proton Mediastinal Radiation for Stage III Lung Cancer: The Best of Both Worlds? Journal of Thoracic Oncology 2012.

30. A. Fernandes, E. Xanthopoulos, T. Evans, J. Stevenson, E. Alley, C. Aggarwal, C. Langer, C. Simone, R. Rengan: Predictive Factors for Mediastinal Nodal Failure in Locally Advanced Non-small Cell Lung Cancer (NSCLC) Patients Receiving Definitive Chemoradiation (CRT) Journal of Thoracic Oncology 2012.

31. A. H. Kesarwala, C. Ko, W. P. O'Meara, H. Ning, K. E. Haglund, E. Xanthopoulos, R. Rengan: Feasibility of Proton Therapy For Elective Nodal Irradiation in Patients with Locally Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology 2012.

32. A. H. Kesarwala, D. J. Lu, E. Xanthopoulos, S. Apisarnthanarax, T. Evans, C. Aggarwal, R. B. Cohen, C. J. Langer, R. Rengan, C. B. Simone: The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Prior to Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer Journal of Thoracic Oncology 2012.

33. A. Milby, R. Mick, J. Turowski, K. Cengel, N. Farnese-McFarlane, C. Mesaros, J. Lawson, M. Christofidou-Solomidou, J. Lee, R. Rengan: Phase I Randomized Trial of Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation Journal of Thoracic Oncology 2012.

34. B. Teo, M. Grupp, M. Kirk, P. Bloch, R. Munbodh, G. Song, J. Gee, R. Rengan: Assessment of Weekly Lung Ventilation Changes During Radiotherapy using 4D-CT Journal of Thoracic Oncology 2012.

35. D. A. Palma, S. Senan, K. Tsujino, R. B. Barriger, R. Rengan, M. Moreno, J. D. Bradley, T. Hyun Kim, L. B. Marks, G. Rodrigues: Predicting Symptomatic Radiation Pneumonitis after Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer: Results of an International Individual Patient Data Meta-analysis Journal of Thoracic Oncology 2012.

36. E. Xanthopoulos, M. Corradetti, S. Grover, A. Fernandes, M. Kim, C. Simone, S. Apisarnthanarax, L. Lin, R. Rengan: A Strategy To Reduce Acute Toxicity From Chemoradiation Therapy For Limited-stage Small Cell Lung Cancer Journal of Thoracic Oncology 2012.

37. G. Maquilan, S. Grover, E. Xanthopoulos, T. L. Evans, C. Aggarwal, C. J. Langer, R. B. Cohen, J. P. Stevenson, C. Simone, R. Rengan: Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small-Cell Lung Cancer Receiving Sequential Treatment. Journal of Thoracic Oncology 2012.

38. M. N. Corradetti, E. Xanthopoulos, S. Cheng, D. Horowitz, A. Fernandes, A. Lusa, C. Chao, R. Rengan: Decreased Overall Survival after Prophylactic Cranial Irradiation for Non-Small Cell Lung Cancer Journal of Thoracic Oncology 2012.

39. R. Rengan, N. Mitra, K. Liao, K. Armstrong, A. Vachani: Impact Of HIV Infection On Survival In Lung Cancer Patients In The Era Of HAART: A SEER-Medicare Analysis Journal of Thoracic Oncology 2012.

40. S. Sharma, J. T. Whaley, W. Zou, A. T. Fernandes, E. Xanthopoulos, C. B. Simone, J. P. Christodouleas, S. Both, R. Rengan, S. Apisarnthanarax: Incidental Nodal Irradiation in Stage III Lung Cancer Treated with Involved Field

Radiation: Comparison Between 3dcrt and IMRT. Journal of Thoracic Oncology 2012.

41. Radiation Injury to the Normal Brain Measured by 3D-Echo-Planar Spectroscopic Imaging and Diffusion Tensor Imaging: Initial Experience. Chawla S, Wang S, Kim S, Sheriff S, Lee P, Rengan R, Lin A, Melhem E, Maudsley A, Poptani H. J Neuroimaging. 2013 Nov 26. doi: 10.1111/jon.12070. [Epub ahead of print] PubMed PMID: 24279509.

42. C. Twyman, A. Rech, R. Rengan. R. Vonderheide, A. Minn: Stereotactic Body Radiation Therapy and CTLA-4 Blockade as a Novel Therapy for Advanced Melanoma Journal for ImmunoTherapy of Cancer November 2013

43. T. Wong, G MacLennan, Q. Dang, K McCune, R. Rengan: Evaluation of Treatment Plan Robustness with Adaptive Re-planning for Recurrent Lung Cancer Patients Treated with Protons. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

44. M. Heskel, E.P. Xanthopoulos, A.T. Berman, W. Levin, A. Vachani, A. Haas. D.H. Sterman, A. Lanfranco, E. Moon, M.N. Corradetti, S.M. Hahn, K.A. Cengel, R. Rengan, C.B. Simone: Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Reirradication for New or Recurrent Pulmonary Malignancies Following Previous In-field Conventionally Fractionated Thoracic Radiotherapy (CFRT). Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

45. M.J. Nyflot, P.E. Kinahan, G.A. Sandison, R. Miyaoka, S.A. Patel, H.J. Vesselle, J. Zeng, R. Rengan: Negative Correlation Between Quantitative FDG PET/CT and MAA SPECT/CT Blood Perfusion Imaging Parameters in Thoracic Malignancy Patients. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

46. P.J. Bremjit, G.D. Robinson, R.L. Weaver, S.R. Bowen, R. Rengan, S.A. Patel. Is Overall Treatment Time a Predictive Factor in Radiation Therapy for Non-Small Cell Lung Cancer? Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

47. S. Senan, C. Oberije, K. Tsujino, T. Wiersma, M. Moreno-Jimenez, T. Kim, L.B. Marks, R. Rengan, L. De Petris, S. Ramella, K. DeRuyck, N. Rodriguez De Dios, A. Warner, J.D. Bradley, D.A.Palma. Is Intermediate Radiation Dose Escalation with Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer Beneficial? A Multi-Institutional Propensity-Score Matched Analysis. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

48. S.R. Bowen, G. Dhami, M.J. Nyflot, P.E. Kinahan, G.A. Sandison, R. Miyaoka, S.A. Patel, H.J. Vesselle, J.Zeng, R. Rengan: Impact of Functional Lung Imaging Using Ventilation/Perfusion SPECT/CT on Planning Objectives in Thoracic Radiation Therapy. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

49. C.B. Simone, M. Heskel, E.P. Xanthopoulos, M.N. Corradetti, S. Singhai, J.S. Friedberg, T.T. Pechet, J.C. Kucharczuk, J.P. Christodouleas, W. Levin, K.A. Cengel, R. Rengan, S.M. Hahn: Stereotactic Body Radiotherapy (SBRT) for Stage I Non-Small Cell Lung Cancer (NSCLC): Outcomes by Fractionation, Tumor Stage and Location, and Patient Operability. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

50. G. Dhami, S.R. Bowen, M. Nyflot, P.E. Kinahan, G.A. Sandison, R.S. Miyaoka, H.J. Vesselle, S.A. Patel, R. Rengan, J. Zeng: Anatomic Variations in Pulmonary Perfusion and Ventilation Per Quantitative MAA and DTPA SPECT/CT in

Patients Receiving Thoracic Radiation Therapy. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

51. P. Richard, M. Phillips, J. Zeng, L. Halasz, L. Fang, S. Apisarnthanarax, R. Rengan: Development of a Multi-Parametric Cost Effectiveness Model for Comparison of Therapeutic Modalities in Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer (NSCLC). Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

52. M. Heskel, E.P. Xanthopoulos, R.B. Cohen, C. Aggarwal, T. Evans, E. Alley, K. Algazy, A.T. Berman, W. Levin, K.A. Cengel, C.J. Langer, R. Rengan, C.B. Simone: Stereotactic Body Radiation Therapy for Oligometastatic Pulmonary Lesions. Accepted for presentation at ASTRO Annual Meeting 2014 (in press)

16. Invited Lectures 1. May, 1998 “The role of Wiskott-Aldrich syndrome protein in signaling cytoskeletal

Remodeling”, Moses Gunn Annual Research Conference, Ann Arbor, MI

2. Mar, 2000 “Actin cytoskeletal function is spared, but apoptosis is increased in WAS patient hematopoiectic cells”, Moses Gunn Annual Research Conference, Ann Arbor, MI

3. Apr, 2007 “The variety of roles of radiation for thoracic malignancies”, Multidisciplinary Management of Lung Cancer and Emphysema, Rittenhouse Hotel, Philadelphia, PA

4. May, 2007 “Radiotherapeutic management of lung cancer”, Holy Redeemer Hospital Grand Rounds, Philadelphia, PA

5. Sep, 2007 “The role of radiation therapy in the management of lung cancer”, Cooper Hospital Oncology Grand Rounds, Camden, NJ

6. Jan, 2008 “The role of imaging in treatment planning for lung cancer”, Joint Radiation Oncology/Radiology Imaging Workshop, Stemmler Auditorium, University of Pennsylvania School of Medicine

7. Feb, 2008 “The local control problem in locally advanced non-small cell lung cancer: Dose escalation and beyond”, Visiting Professorship, Drexel University Department of Radiation Oncology, Philadelphia, PA

8. May, 2008 “The current utilization of PET/CT in radiation oncology: Panel discussion with case studies”, Sheraton University City Hotel, Philadelphia, PA

9. May, 2008 “The multidisciplinary approach to lung cancer at Penn”, Abramson Cancer Center Annual Donor Event, University of Pennsylvania School of Medicine

10. Aug, 2008 “Improving local control in locally advanced NSCLC: Sisyphean challenge or attainable goal?”, Lynn Cancer Center Grand Rounds, Boca Raton Community Hospital, Miami, FL

11. Sep, 2008 “The radiation oncologists dilemma: How do we improve local control in locally advanced NSCLC?”, Abramson Cancer Center Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, PA

12. Sep, 2008 “Early stage NSCLC: A discussion of presented abstracts”, Radiation Oncology Symposium, American Society for Therapeutic Radiation and Oncology (ASTRO) Annual Meeting, Boston, MA

13. Sep, 2008 “Elective nodal irradiation versus involved field radiotherapy for non small cell lung cancer”, Masters in Radiation Oncology Symposium, American Society for Therapeutic Radiation and Oncology (ASTRO) Annual Meeting, Boston, MA

14. Sep, 2008 “The management of non-small cell lung cancer and difficult case management paradigms”, NCI Radiation Oncology Branch Visiting Professorship, National Cancer Institute (NCI), Bethesda, MD

15. Oct, 2008 “Radiation oncology at Abramson Cancer Center: Past, present, and Future”, Abramson Cancer Center Penn Medicine Campaign Cabinet Meeting, Inn at Penn, Philadelphia, PA

16. Oct, 2008 “Combined modality therapy with Nelfinavir in NSCLC: A novel approach to radiosensitization”, The Eli Glatstein, MD Translational Research Conference: “New Paradigms in Radiation Oncology”, Ritz-Carlton Hotel, Philadelphia, PA

17. Nov, 2008 “Multimodality therapy of non-small cell lung cancer. A discussion of presented abstracts”, Multidisciplinary Symposium on Thoracic Oncology, Chicago, IL

18. Nov, 2008 “Multidisciplinary treatment paradigms in the management of non-small cell lung cancer: A discussion of presented abstracts”, Multidisciplinary Thoracic Oncology Symposium, Marriott Hotel, Chicago, IL

19. May, 2009 “Radiation treatment of malignant melanoma”, Focus on Melanoma Patient Symposium, Hilton City Line Hotel, Philadelphia, PA

20. Jun, 2009 “The promise and perils of proton beam radiotherapy”, Taylor Hospital Grand Rounds, Ridley Park, PA

21. Sep, 2009 “The role of neoadjuvant radiotherapy in the management of locally advanced NSCLC”, Multidisciplinary Management of Lung Cancer, Emphysema, and Benign Airway Disease, Hyatt Regency at Penns Landing, Philadelphia, PA

22. Oct, 2009 “Radiation treatment of locally advanced NSCLC”, Abramson Cancer Center's “Focus on Lung Cancer Symposium”68, Hilton City Line Hotel, Philadelphia, PA

23. Apr, 2010 “The role of functional imaging in the radiotherapeutic management of lung cancer”, Functional Imaging in Radiotherapy Symposium, University of British Columbia, Vancouver, Canada

24. Jun, 2010 “The role of functional imaging in radiotherapy planning for non-small cell lung cancer”, Symposium on the Big Bore PET/CT and Tomotherapy, Jeddah, Saudi Arabia

25. Jun, 2010 “The role of functional imaging in radiotherapy planning for non-small cell lung cancer”, Symposium on Tomotherapy and Image Guided Radiotherapy, Riyadh, Saudi Arabia

26. Jun, 2010 “Lung cancer as a target for proton therapy”, Symposium for Image Guided Radiotherapy, World Conference on Interventional Oncology, Philadelphia, PA

27. Sep, 2010 “How PET/CT imaging can improve target delineation for radiotherapy of lung cancer”, Symposium on Advances in Radiotherapy Imaging and Treatment Planning, 29th Annual Meeting of the European Society for Therapeutic Radiology, Barcelona, Spain

28. Sep, 2010 “The local control problem in locally advanced non-small cell lung cancer”, Visiting Professorship, Radiation Oncology Grand Rounds, Oregon Health Sciences University, Portland, OR

29. Oct, 2010 “Can functional imaging improve the therapeutic ratio for radiotherapy In lung cancer?”, European Association of Nuclear Medicine, Vienna, Austria

30. Oct, 2010 “Integration of functional imaging into the therapeutic paradigm for lung cancer”, American Society for Therapeutic Radiology and

Oncology (ASTRO) Annual Meeting, San Diego, CA 31. Oct, 2010 “Expanding oncology care: Functional imaging for radiation treatment

planning and quality assurance with Gemini time of flight big bore PET/CT”, Breakfast Symposium on PET/CT Workflow in Radiation Therapy and Intensity Modulated Radiation Therapy, Annual Congress of the European Association of Nuclear Medicine, Vienna, Austria

32. Oct, 2010 “Can functional imaging improve the therapeutic ratio for radiotherapy in lung cancer?”, Satellite Symposium on, “Meaningful innovations: Adding new dimensions in multimodality imaging”, Congress of the European Association of Nuclear Medicine Vienna, Austria

33. Mar, 2011 “The role of functional imaging in radiation treatment planning for lung cancer”, Symposium of Association of Indian Nuclear Medicine Physicians, Hotel Ramada Plaza, Delhi, India

34. Mar, 2011 “Pulmonary functional imaging and its application to thoracic radiation oncology”, International Pulmonary Functional Imaging Workshop, University of Pennsylvania, Philadelphia, PA

35. Mar, 2011 “The evolving role of functional imaging in radiation treatment planning for lung cancer”, Tata Memorial Hospital Nuclear Medicine Grand Rounds, Tata Memorial Hospital, Mumbai, India

36. Mar, 2011 “The impact of tumor biology on local control in NSCLC”, Visiting Professorship, Ellis Fischel Cancer Center University of Missouri, Columbia, MO

37. May, 2011 “Leveraging radiation and surgery to improve local control in non-small cell lung cancer”, Fox Chase Cancer Center Thoracic Surgery Grand Rounds, Philadelphia, PA

38. Jul, 2011 “Adjuvant radiotherapy for thymoma”, Invited Speaker, 14th World Conference on Lung Cancer, Amsterdam, Netherlands

39. Sep, 2011 “Dose Escalation for Locally Advanced NSCLC: Implications of RTOG 0617”, NCI Radiation Oncology Branch Visiting Professorship, National Cancer Institute (NCI), Bethesda, MD

40. Dec, 2011 “The Impact of PET/CT in Radiotherapy Planning for Lung Cancer”, Invited Presentation at the Annual Meeting of the Society of Nuclear Medicine-India, Presented in Chennai

41. Dec, 2011 “The role of Functional Imaging in Radiotherapy of Locally Advanced NSCLC and Head and Neck Cancer”, Visiting Professor, Madras Medical College, Chennai

42. Feb, 2012 “A phase I/II trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for stage IIIA/IIIB NSCLC”; presented at the ACC Radiobiology and Imaging Symposium, University of Pennsylvania, Philadelphia, PA

43. Mar, 2012 “The impact of PET/CT in radiotherapy treatment planning for lung cancer”, Invited presentation at the 4th Annual Saudi Nuclear Medicine Physicians Meeting, Istanbul, Turkey

44. Mar, 2012 “Functional imaging for radiation treatment planning”, Invited presentation at the 4th Annual Saudi Nuclear Medicine Physicians Meeting, Istanbul, Turkey

45. Apr, 2012 “Combined modality therapy for Stage III NSCLC: Current status and future directions”, IASLC Regional Symposium, Cohen Hall, University of Pennsylvania, Philadelphia, PA

46. Apr, 2012 “Optimizing the therapeutic ratio for radiotherapy in locally advanced NSCLC” Visiting Professorship, Henry Ford Hospital, Detroit, MI

47. Jun, 2012 “Phase II clinical trial design for radiation oncologists” invited lecture at the Penn Radiation Oncology Clinical Trials Course Philadelphia, PA

48. Sep, 2012 “Radiosensitization with Nelfinavir in locally advanced NSCLC and an initial discussion of RADVAX- an emerging concept in radiotherapy” Invited lecture Radiobiology and Imaging Lecture Series Abramson Cancer Center, University of Pennsylvania

49. Sep, 2012 “Integration of targeted therapies into chemoradiotherapy for locally advanced NSCLC” Invited lecture at the Multidisciplinary Symposium on Thoracic Oncology Chicago, IL

50. Oct, 2012 “The tumor microenvironment as a target for the HIV Protease Inhibitor Nelfinavir in Stage IIIA/IIIB NSCLC: Early Clinical Trial Results and Interpretations” Tumor microenvironment and cellular stress: Signaling, metabolism, imaging, and therapeutic targets” Crete, Greece

51. Nov, 2012 “Approaching early stage NSCLC: surgery vs. SBRT vs. RFA” Invited lecture at Perspectives in Thoracic Oncology, New York, NY

52. Dec, 2012 “Improving the therapeutic ratio for radiotherapy of locally advanced NSCLC” Tufts Cancer Center Grand Rounds Boston, MA

53. Feb, 2013 “Functional imaging and targeted therapies in locally advanced NSCLC” Cancer Imaging and Radiotherapy Symposium Orlando, FL

54. Mar, 2013 “Evolving strategies in radiotherapy for lung cancer” Invited lecture at 14th Annual Sun, Sand,Seeds Conference Boca Raton, FL

55. Mar, 2013 “The management of lung cancer” Invited lecture at the ASTRO Spring Refresher Course Chicago, IL

56. Mar, 2013 “Contraindications with radiotherapy-emerging data” Invited lecture at the ASTRO Spring Refresher Course Chicago, IL

57. Mar, 2013 “Critical radiotherapeutic clinical alerts” Invited lecture a ASTRO Spring Refresher Course Chicago, IL

58. Jun, 2013 “Proton beam radiotherapy” Invited lecture at UW Neighborhood Clinic Executive Committee

59. Sep, 2013 “Thoracic Journal Club” Associate Medical Director SCCA Proton Center, Associate Professor Department of Radiation Oncology

60. Oct, 2013 “Targeted therapy and stereotactic body radiation therapy” WCLC 2013 Sydney, Australia

61. Oct, 2013 “Improving the therapeutic ratio in NSCLC: role of particle beam therapy” New South Wales Cancer Center

62. Jan, 2014 “Medical Director: Vision for the Proton Center 2014” Invited lecture at the 2nd Annual Medical Leadership Dinner

63. Feb, 2014 “RADVAX: SBRT and Ipilimumab in metastatic melanoma” Melanoma Research Alliance Scientific Retreat Washington, DC

64. Mar, 2014 “Critical Clinical Updates: Thoracic” ASTRO Spring Refresher Course, New Orleans, LA

65. Mar, 2014 “The management of lung cancer” ASTRO Spring Refresher Course, New Orleans, LA

66. Apr, 2014 “Protons and carbon ions to improve the therapeutic index of radiation therapy” AACR Annual Meeting, San Diego, CA

67. Sep, 2014 “Challenges and Solutions for a Successful Physician-Scientist Career in Radiation Oncology” ASTRO Annual Meeting, San Francisco, CA

68. Oct, 2014 “Proton Beam Radiotherapy in Thoracic Tumors: Future Directions” Particle Therapy Group, North America Annual Meeting, Houston, TX

69. Nov, 2014 “Best of ASTRO Annual Meeting Thoracic Presentations” Washington State Radiological Society Annual Meeting Kirkland, WA

70. Nov, 2014 “Emerging Applications for Radiotherapy in Cancer Immunotherapy” FHCRC Immunotherapy Seminar, Seattle, WA

71. Mar, 2015 “Proton Beam Radiotherapy in Thoracic Tumors: Clinical Potential and Daunting Challenges” IBA Users Meeting, Philadelphia, PA

72. Mar, 2015 “Can Particle Beam Therapy Improve the Therapeutic Window for NSCLC” Stanford University Department of Radiation Oncology, Stanford, CA

73. Mar, 2015 “The Challenge of Treating NSCLC with Radiation: Is There a Role for Protons” SCCA Proton Outreach Lecture, Pasco, WA

74. May, 2015 “The Role of Radiotherapy in the Management of Malignant Pleural Mesothelioma” SCCA Thoracic Symposium Seattle, WA

75. May, 2015 “The Role of Particle Beam therapy in Locally Advanced NSCLC” American Radium Society Annual Meeting Presidential Course, Kona, Hawaii

76. May, 2015 “The Role of Proton Beam Radiotherapy in Solid Tumors” SCCA Anchorage Oncology Outreach Dinner, Anchorage, Alaska

77. July, 2015 “The Role of Proton Beam Radiotherapy in the Management of Solid Tumors” Apollo Hospital Proton Center CME, India

78. Aug, 2015 “Proton Beam Radiotherapy in Thoracic Tumors: Clinical Potential and Daunting Challenges” IBA Users Group, Louvain-La-Neuve, Belgium

79. Oct, 2015 “Widening the Therapeutic Ratio for Radiotherapeutic Management of Locally Advanced NSCLC: Particles, Tumor Biology, and Immune Modulation” ASTRO Annual Meeting, San Antonio, Texas

80. Oct, 2015 “The Role of Protons in the Management of Locally Advanced Breast Cancer” SCCA Symposium on Challenges and Controversies in Breast Cancer, Seattle, WA

81. Nov, 2015 “Combination of Stereotactic Ablative Body Radiation with Targeted Therapies” 2nd Hong Kong International Oncology Symposium, Hong Kong, China

82. Nov, 2015 “The Role of Proton Therapy in Locally Advanced NSCLC” 2nd Hong Kong International Oncology Symposium, Hong Kong, China

83. Nov, 2015 “The Strengths and Limitations of the Current Therapeutic Paradigm for Thoracic Malignancies” SCCA Proton Therapy Thoracic Lung Symposium, Seattle, WA

84. Feb, 2016 “Improving the Therapeutic Ratio with Proton Beam Radiotherapy in Locally Advanced NSCLC” Visiting Professor, Georgetown University Department of Radiation Medicine Grand Rounds, Washington, D.C.

84. Feb, 2016 “The Role of Proton Beam Radiotherapy in Management of NSCLC” International Association for the Study of Lung Cancer Webinar

85. Mar, 2016 “Summary from the Thoracic Focus Group: The Role of Proton Therapy in Thoracic Malignancies” IBA Users Meeting, Trento, Italy

86. Mar, 2016 “Radiation Therapy Contraindications and Safety Panel: Re-Irradiation, Novel Combination Therapies, and Hypofractionation” 2016 ASTRO Annual Refresher Course, La Jolla, CA

87. April, 2016 “Improving the Therapeutic Ratio with Proton Beam Radiotherapy in Locally Advanced NSCLC” Columbia University Medical Center, NY, NY

88. May, 2016 “Phase II Clinical Trial Design for Radiation Oncology” OHSU Clinical Trials Course, Portland, OR

89. May, 2016 “Particle Beam Based Clinical Trial Design for Radiation Oncology” OHSU Clinical Trials Course, Portland, OR